Trial Profile
PERSISTENCE OF MAJOR MOLECULAR REMISSION IN CHRONIC MYELOID LEUKEMIA AFTER a second stop of TKI TREATMENT in patients who failed an initial stop attempt: A prospective multicenter study .
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2019
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DASTOP2
- 09 Mar 2017 New trial record